The FDA declared the end of the shortage of Novo Nordisk’s Wegovy and Ozempic, impacting compounding pharmacies selling ...
24/7 Wall St. on MSN38m
Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...
Investor's Business Daily on MSN2h
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs ShortageHims stock dropped sharply Friday after the U.S. Food and Drug Administration said the shortage of widely-used weight-loss ...
Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.
The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...
The U.S. drug regulator declared that the shortage of weight-loss medications Wegovy and Ozempic has been resolved, Danish pharma giant Novo Nordisk said.
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback